within Pharmacolibrary.Drugs.ATC.A;

model A03BB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.22 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.128,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Butylscopolamine, also known as hyoscine butylbromide, is a peripherally-acting antimuscarinic agent commonly used as an antispasmodic for the treatment of abdominal pain and cramps associated with gastrointestinal and genitourinary tract disorders. It does not cross the blood-brain barrier, minimizing central nervous system effects. Butylscopolamine is widely approved and used in many countries today.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Yamamoto, F, et al., &amp; Tamaki, N (2004). Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. <i>Annals of nuclear medicine</i> 18(7) 637–640. DOI:<a href=&quot;https://doi.org/10.1007/BF02984589&quot;>10.1007/BF02984589</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15586641/&quot;>https://pubmed.ncbi.nlm.nih.gov/15586641</a></p></li><li><p>Emmott, J, et al., &amp; Wong, WL (2008). The effects of N-butylscopolamine on bowel uptake: an 18F-FDG PET study. <i>Nuclear medicine communications</i> 29(1) 11–16. DOI:<a href=&quot;https://doi.org/10.1097/MNM.0b013e3282f1d706&quot;>10.1097/MNM.0b013e3282f1d706</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18049092/&quot;>https://pubmed.ncbi.nlm.nih.gov/18049092</a></p></li><li><p>Tytgat, GN (2008). Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. <i>Current medical research and opinion</i> 24(11) 3159–3173. DOI:<a href=&quot;https://doi.org/10.1185/03007990802472700&quot;>10.1185/03007990802472700</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18851775/&quot;>https://pubmed.ncbi.nlm.nih.gov/18851775</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03BB01;
